SCHEMBL1067371

SCHEMBL1067371

CC(C)C[C@@H](C(=O)O)N1CC(Oc2ccc(F)cc2F)=CC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 2/20 0.38
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CARM1 Q86X55 3/20 0.35
PRMT6 Q96LA8 3/20 0.35
MAPK14 Q16539 5/20 0.34
MAPK8 P45983 2/20 0.34
CREBBP Q92793 1/20 0.34
BRD4 O60885 4/20 0.34
GHSR Q92847 1/20 0.33
RPS6KA4 O75676 1/20 0.33
MAPK9 P45984 1/20 0.33
CSNK1E P49674 1/20 0.33
RPS6KA3 P51812 1/20 0.33
MAPK10 P53779 1/20 0.33
MAPK11 Q15759 1/20 0.33
NLK Q9UBE8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067375 1.00 S1PR2 (0.38) S1PR2MEN1MAPTHPGDKMT2A
SCHEMBL1067314 0.91 HIF1A (0.33) HIF1A
SCHEMBL1067318 0.91 HIF1A (0.33) HIF1A
SCHEMBL1067449 0.91 S1PR2 (0.36) S1PR2MEN1MAPTHPGDKMT2A
SCHEMBL1067446 0.91 S1PR2 (0.36) S1PR2MEN1MAPTHPGDKMT2A
SCHEMBL1069346 0.90 CXCL8 (0.40) MAPTHPGDCARM1PRMT6
SCHEMBL1069348 0.90 CXCL8 (0.40) MAPTHPGDCARM1PRMT6
SCHEMBL1068465 0.84 SLC6A2 (0.33) L3MBTL1
SCHEMBL1065620 0.84 SLC6A2 (0.33) L3MBTL1
SCHEMBL1063687 0.83 MME (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US claimed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US claimed
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 S1PR2 3011/4885MEN1 2997/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.